Company Overview and News

Top Research Reports for Walmart, AT&T & Novo Nordisk

2018-05-18 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), AT&T (T) and Novo Nordisk (NVO). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

Buy Fox Now, Not Disney

2018-05-18 seekingalpha
Comcast is preparing to enter the fray depending on the result of AT&T's merger with Time Warner.

A Peek Into Latest 13-F Filing: Top Hedge Fund Stocks

2018-05-18 zacks
Investors have started mulling over the top bets of big investors like Bill Ackman, George Soros, Carl Icahn, David Tepper, Larry Robbins, Leon Cooperman, Daniel Loeb, David Einhorn and Stanley Druckenmiller, following the first-quarter release of 13F Forms. The group, often known as hedge funds and shifting composition, has outperformed the broad stock market this year after nearly a decade of underperformance.

Tracking John Paulson's Paulson & Co. Portfolio - Q1 2018 Update

2018-05-18 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking John Paulson's Paulson & Co. Portfolio series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017.

The MnM Portfolio - Reviewing May 2018 Fundamentals

2018-05-18 seekingalpha
While the market still has relatively high valuations overall, there are positions in the portfolio with attractive multiples.

CBS and Viacom better off with other suitors: Analyst Barton Crockett

2018-05-17 cnbc
The best outcome for CBS and Viacom would be other suitors for the companies, analyst Barton Crockett told CNBC on Thursday.

Is the 1-minute commercial break the future of TV?

2018-05-17 money.cnn
Fox Networks Group -— the division of 21st Century Fox (FOXA) that controls the company's broadcast, cable and sports channels — says it will shorten commercial breaks during some of its programs to one minute, or two 30-second spots back to back.

Redstone Family Defeats CBS Bid to Undercut Control of Firm - Bloomberg

2018-05-17 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Looking into T-Mobile’s Q1 2018 Performance

2018-05-17 marketrealist
T-Mobile (TMUS) started the year with impressive earnings results in the first quarter of 2018. The telecom (telecommunications) company exceeded Wall Street analysts’ expectations for both earnings and revenue. It’s been consistently delivering better-than-expected earnings results for the past several quarters.

Tracking George Soros' Portfolio - Q1 2018 Update

2018-05-17 seekingalpha
Soros' 13F portfolio value increased from $4.37B to $6.16B this quarter. The number of positions increased from 196 to 219.

These ‘Dividend Aristocrat’ stocks have risen as much as 31% this year, bucking a bad trend - MarketWatch

2018-05-17 marketwatch
Popular consumer companies have underperformed, but a group including W.W. Grainger, T. Rowe Price and AbbVie are easily beating the S&P 500

Franchises to Aid Disney Survive Netflix & Amazon Onslaught

2018-05-17 zacks
Disney (DIS) continued its fairytale ride at the box office with back-to-back success of Black Panther and Avengers: Infinity War. In fact, the success provided a huge boost to the media giant’s strategy of monetizing franchises from acquired studios like Marvel and Lucasflim. This is evident from the recent box office collections. Per data from Box Office Mojo, Black Panther currently tops the U.S.

Top Merger Stocks Held By Fund Managers, Mid-Q2 2018

2018-05-17 seekingalpha
Each quarter, I spend a day or two reading Form 13F filings from the hedge funds that specialize in merger arbitrage, documenting and analyzing which merger stocks the funds have bought and which ones they haven't. I then compile the top 10 stocks held in these funds and share it with the Seeking Alpha community.

Giuliani’s media work for Trump may backfire on his business

WASHINGTON— Lawyer Rudy Giuliani’s decision to join President Donald Trump’s legal team could backfire on the former New York mayor if potential clients of his international consulting business view him as too erratic and go elsewhere for representation, according to legal experts.

Judge Hits Pause on War Between CBS and Its Parent Company - The New York Times

2018-05-17 nytimes
When he took the stage at Carnegie Hall during CBS’s annual presentation to advertisers on Wednesday, Stephen Colbert did not shy away from the topic on the minds of everyone in the audience.

Related Articles

SQ: Square Analysis and Research Report

7h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

TROV: TrovaGene Analysis and Research Report

8h - Asif

BUSINESS TrovaGene is a clinical-stage, precision medicine oncology therapeutics company. The company's primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) technology in tumor genomics. The company's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other hematologic and solid tumor cancers. On March 15, 2017, the company announced the licensing of PCM-075, a PLK1 inhibitor...

SGMO: Sangamo BioSciences Analysis and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

CUSIP: 887317303